🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07115511
Recruiting Not applicable

Combined Recanalization Therapy for Acute Large Vessel Occlusion Stroke

NCT07115511 · tracked via the Priya Life Science China tracker
Sponsor
Tianjin Huanhu Hospital
Phase
Not applicable
Started
2024-12-01
Last updated
2025-08-11

Condition(s) studied

Stroke

Investigational drug(s) / intervention(s)

Surgery

Surgery: Recombined recanalization surgery

Study summary

The purpose of this clinical trial is to evaluate the efficacy and safety of combined recanalization therapy in patients who cannot be recanalized by acute large vessel occlusive stroke. The main questions it aims to answer are:

1、Proportion of subjects with mRs score of 0-1 at 90 days after surgery

Participants will:

1、In acute large vessel occlusive stroke, if traditional means cannot be recanalized, combined recanalization surgery (including arteriotomy and thrombectomy, cerebrovascular bypass surgery) is performed.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: 1. Age: 18-75. 2. According to the current guidelines, there is a MT indication. 3. Before stroke, mRS ≤2; 4. ASPECTS ≥6; 5. MCA occlusion, with or without ICA occlusion; 6. MT unsuccessful, TICI score 0-1; 7. Time from onset to craniotomy expected to be 24 hours or less; 8. Post-awakening stroke with mismatch between the infarct zone and the penumbra zone; Exclusion Criteria: 1. Comorbid hemorrhagic vascular disease such as intracranial aneurysm or vascular malformation or other planned cerebrovascular surgery that may alter cerebral hemodynamics or lead to stroke; 2. unstable angina or myocardial infarction, congestive heart failure within the previous 6 months; 3. Pregnancy or perinatal period; 4. Hematologic disorders resulting in coagulation disorders; 5. Combination of other diseases with a life expectancy of less than 2 years; and 6. previous treatment with intracranial or extracranial vascular bypass surgery; 7. allergy to iodine or X-ray contrast media, creatinine \>3.0 mg/dl or other contraindications to arteriography; 8. Uncontrolled diabetes mellitus, fasting blood sugar (FBS) \>16.7 mmol/L; 9. Uncontrolled hypertension with sitting systolic blood pressure \>180 mmHg or sitting diastolic blood pressure \>110 mmHg; 10. Severe hepatic dysfunction, defined as serum alanine aminotransferase (ALT) and/or alanine aminotransferase (AST) \>3 times the upper limit of normal; 11. Platelets \<100×109 /L. 12. Received a clinical trial drug or device within 30 days prior to screening, or is participating in another clinical trial; 13. contraindication to general anesthesia or craniotomy; 14. other diseases or medical history that, in the investigator's judgment, may affect the efficacy or safety evaluation of this study.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Tianjin Huahu Hospital Tianjin Tianjin Municipality Recruiting

More Tianjin Huanhu Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07115511 on ClinicalTrials.gov ↗ ← All trials in China